KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Gross Margin: 2010-2024

Historic Gross Margin for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to 73.55%.

  • Emergent BioSolutions' Gross Margin rose 456.00% to 62.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 105.83%, marking a year-over-year increase of 679.00%. This contributed to the annual value of 73.55% for FY2024, which is 268.00% up from last year.
  • Latest data reveals that Emergent BioSolutions reported Gross Margin of 73.55% as of FY2024, which was up 3.78% from 70.88% recorded in FY2023.
  • Emergent BioSolutions' Gross Margin's 5-year high stood at 75.97% during FY2022, with a 5-year trough of 57.82% in FY2021.
  • Its 3-year average for Gross Margin is 73.47%, with a median of 73.55% in 2024.
  • As far as peak fluctuations go, Emergent BioSolutions' Gross Margin plummeted by 813bps in 2021, and later spiked by 1,815bps in 2022.
  • Over the past 5 years, Emergent BioSolutions' Gross Margin (Yearly) stood at 65.95% in 2020, then crashed by 813bps to 57.82% in 2021, then surged by 1,815bps to 75.97% in 2022, then slumped by 510bps to 70.88% in 2023, then soared by 268bps to 73.55% in 2024.